pocketful logo
Emmessar Biotech & Nutrition Ltd logo

Emmessar Biotech & Nutrition Ltd

NSE: BSE: 524768

₹25.91

(-3.64%)

Tue, 03 Mar 2026, 00:22 pm

mtf coin illustrationMTF 5x

Emmessar Biotech & Nutrition Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    12.22

  • Net Profit

    0.32

  • P/B

    1.97

  • Sector P/E

    40.39

  • P/E

    48.24

  • EV/EBITDA

    7.85

  • Debt/Equity (Industry)

    0.41

  • Interest Cover (Industry)

    2.83

  • ROCE (Industry)

    5.60

  • RONW (Industry)

    3.91

  • ROE

    4.23

  • ROCE

    11.52

  • Debt/Equity

    0.01

  • EPS (TTM)

    0.67

  • Dividend Yield

    0

  • Book Value

    15.99

  • Interest Cover

    0

Analysis

all

thumbs up icon

Pros

  • Emmessar Biotech & Nutrition is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
  • Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
  • Emmessar Biotech & Nutrition has no debt, it does not need to be covered by operating cash flow.
  • Emmessar Biotech & Nutrition has no debt, it does not need to be covered by short term assets.
thumbs up icon

Cons

  • Unable to evaluate Emmessar Biotech & Nutrition's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Emmessar Biotech & Nutrition's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • High level of physical assets or inventory.
  • Emmessar Biotech & Nutrition is not covered by any analysts.
  • Emmessar Biotech & Nutrition's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters59.5359.5359.5359.5359.53
FII00000
DII0.200.200.200.200.20
Public40.2840.2840.2840.2840.28
Government00000

Read More

Technical Analysis

RSI

39.01

MACD

-0.60

50 DMA

27.72

200 DMA

30.47

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic44.2235.9130.9127.6022.6019.2910.98
Fibonacci35.9132.7430.7727.6024.4322.4619.29
Camarilla28.2027.4326.6727.6025.1524.3923.62

Pivots Level: Classic

R3

+16.62

44.22

R2

+8.31

35.91

R1

+3.31

30.91

27.60
27.60
Pivot Point
LTP: 24.43

S1

-5.00

22.60

S2

-8.31

19.29

S3

-16.62

10.98

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    25.94

  • 20-EMA

    26.41

  • 30-EMA

    26.81

  • 50-EMA

    27.50

  • 100-EMA

    28.73

  • 200-EMA

    30.58

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results
07 Aug 2025agm
04 Sept 2024agm
27 Oct 2023egm
24 Aug 2023agm
05 Jul 2022agm
29 Jul 2021agm

Read More

Peer Comparison

Emmessar Biotech & Nutrition Ltd logo

Emmessar Biotech & Nutrition Ltd

Godrej Industries Ltd logo

Godrej Industries Ltd

Linde India Ltd logo

Linde India Ltd

Gujarat Fluorochemicals Ltd logo

Gujarat Fluorochemicals Ltd

SRF Ltd logo

SRF Ltd

Pidilite Industries Ltd logo

Pidilite Industries Ltd

Read More

Emmessar Biotech & Nutrition Ltd About

Emmessar Biotech & Nutrition The Company's primary line of business had been manufacturing and marketing of healthcare & nutritional products.

Industry

Chemicals

Founded

1992

Headquarters

CEO

MSR Ayyangar

Employees

Contact

Website icon

Website

http://www.ebnl.org

Email icon

Email

investors@ebnl.org

Phone icon

Phone

91-022-20870587

Location icon

Location

Plot No T-3/2 MIDC Area, P O Box No 39 Taloja, Raigad, Maharashtra, 410208

Read More

Emmessar Biotech & Nutrition Ltd Company History

YearHistory
2008
  • Emmessar Technologies Private Ltd became Emmessar Technologies Ltd
  • RESQ was launched as an unfailing solution for treating all types of burns from heat and radiation
  • Cute N Comely was launched as a premier topical application with protective and therapeutic properties for skin rejuvenation
2009
  • Frejomus tablets were launched to help mitigate joint pains that restrict movement for the middle and old aged people.
2010
  • Sepecer was launched as a reliable solution for neurological and physiological health for the middle ages and beyond.
2011
  • Psoribalm was launched to meet the long standing demand for a harmless and reliable treatment for Psoriasis.
2016
  • Over 30 newly developed products to meet a spectrum of healthcare needs were ready to be launched progressively from mid 2016 onwards.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
QUANTSEYE AI PRIVATE LIMITEDSell2533329.2929 Jul 2025
SHRENIK DINESH SHAHSell2600043.613 Dec 2024
PRATIBHA DINESH SHAHBuy3818143.613 Dec 2024
AIMS FINANCIAL VENTURESSell2599151.512 Nov 2024
SHRENIK DINESH SHAHBuy2600051.512 Nov 2024
PRACHI PRAKASH RAKTATEBuy3226463.4416 Oct 2024
PRACHI PRAKASH RAKTATESell458962.8516 Oct 2024
AIMS FINANCIAL VENTURESBuy2598661.4216 Oct 2024
MEHUL K MOTABuy250003909 Aug 2021
PRATYUSH MITTALBuy2571941.1407 Jun 2021

Read More

Emmessar Biotech & Nutrition Ltd News

Emmessar Biotech Reports Q3 FY26 Results

Emmessar Biotech & Nutrition Limited reported net profit of ₹11.64 lakhs for Q3 FY26, with revenue from operations at ₹9.34 lakhs. Nine-month profit reached ₹40.17 lakhs.

11 Feb 2026

co actions results

Emmessar Biotech Nutrition Reports Financial Results for Quarter Ended September 30, 2025

Emmessar Biotech Nutrition Limited announced its unaudited financial results for the quarter ended September 30, 2025. The company reported revenue from operations of Rs. 9.26 lakhs for the quarter, compared to Rs. 13.90 lakhs in the previous quarter. The company recorded a net loss after tax of Rs. 3.67 lakhs for the quarter, compared to a net profit of Rs. 30.55 lakhs in the previous quarter. For the half-year period, the company reported revenue of Rs. 23.16 lakhs and net profit after tax of Rs. 26.88 lakhs. The company operates in two segments - Healthcare and Rent on leasehold land. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. The company's paid-up equity share capital stands at Rs. 499.61 lakhs with a face value of Rs. 10 per share.

12 Nov 2025

earnings

Essar: Stanlow Set to Become World's First Decarbonised Green Refinery

<p>Essar plans to <span class='positive'>transform</span> UK's Stanlow refinery using <span class='positive'>blue hydrogen</span>, aiming to <span class='positive'>cut carbon emissions</span> by 95%. The project, part of <b>HyNet</b>, will produce 350MW of blue hydrogen in phase-1 and 1GW in phase-2. The company is also <span class='positive'>developing green mobility solutions</span> and plans to <span class='positive'>invest</span> in <b>LNG</b> and <span class='positive'>electric truck ecosystems</span>.</p>

08 Oct 2024

normal news

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800